文献速递临床试验与 GCP基础与转化研究

氯沙坦改善多韧带膝关节损伤术后结局的随机对照试验(LION试验)

Losartan to Improve Outcomes after multi-ligament kNee injury (LION Trial).
PubMed 文献 · Trials · 2026-04-14

多韧带膝关节损伤术后常因关节纤维化和炎症导致活动度丢失及重返运动困难。LION试验为随机双盲安慰剂对照研究,计划纳入90例多韧带重建患者,术后口服氯沙坦或安慰剂30天,以CORS评分为主要结局,评估氯沙坦对功能恢复、活动度及滑膜炎的改善作用。

要点

  • 多韧带膝损伤术后关节纤维化与炎症影响功能恢复。
  • 氯沙坦30天疗程可能减少关节纤维化并改善活动度。
  • 主要结局为CORS问卷评分,次要结局包括重返活动时间等。

核心结论

  • 氯沙坦可能通过减少关节纤维化和促炎信号改善多韧带膝关节损伤术后一年的手术结局。

研究设计与样本

  • 随机、双盲、安慰剂对照临床试验,计划招募90例接受多韧带膝关节重建的患者。
  • 入组后按1:1随机分配至术后口服氯沙坦或安慰剂30天。

主要发现

  • 主要结局为Cincinnati Occupational Rating Scale(CORS)问卷评分,量化自我报告的身体功能。
  • 次要结局包括术后重返现役、工作或运动的时间、IKDC主观膝关节评分、VAS疼痛评分、膝关节活动度、股四头肌力量及超声评估的持续性滑膜炎。

关键数值与推荐

  • 主要结局:CORS问卷评分。
  • 次要结局:重返活动时间、IKDC评分、VAS疼痛评分、膝关节活动度、股四头肌力量、超声滑膜炎。

临床怎么用

  • 若试验证实有效,氯沙坦这一广泛可用且廉价的药物可能重新定义多韧带重建的围手术期管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multi-ligament knee injuries (MLKI) are complex injury patterns that affect two or more ligaments of the knee. Although surgical intervention can improve functional and clinical outcomes, a large percentage of patients are unable to return to preoperative activity levels. One reason for this is loss of knee range of motion (ROM), which characterizes the exaggerated pro-inflammatory environment of arthrofibrosis and is associated with future osteoarthritis risk. The purpose of this study is to assess the effectiveness of a 30-day course of losartan, a common angiotensin II antagonist, in improving surgical outcomes one year after MLKI surgery by reducing arthrofibrosis and pro-inflammatory signaling. Our hypothesis is that individuals who undergo MLKI reconstruction and take losartan will report an increased ability to return to activity, improved ROM, and decreased synovitis. METHODS: This is a randomized, double-blinded, placebo-controlled clinical trial that aims to recruit 90 patients who are undergoing MLKI reconstruction. Upon enrollment, patients will be randomly assigned to a 30-day postoperative course of oral losartan or placebo on a 1:1 basis. The primary outcome will be the Cincinnati Occupational Rating Scale (CORS) Questionnaire Score which will quantify self-reported physical function. The secondary outcomes will include the time to return to active duty, work, and/or sport after surgery; International Knee Documentation Committee (IKDC) Subjective Knee Scores; Visual Analogue Scale (VAS) Pain Scores; knee ROM; quadricep strength; and ultrasound measures of persistent synovitis. DISCUSSION: There is an unmet need for interventions to reduce inflammation and arthrofibrosis following MLKI to both rescue ROM and improve rates of return to activity. The LION Trial is a randomized, placebo-controlled clinical trial that will evaluate the efficacy of a 30-day course of losartan following MLKI reconstruction. The results of this study have the potential to redefine perioperative management and improve long-term functional outcomes for all patients undergoing ligament reconstruction with a widely available and inexpensive medication. TRIAL REGISTRATION: Clinicaltrials.gov #NCT06933706. Registered on April 11th, 2025.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Kehoe S, Stone A, Yuan X, et al. Losartan to Improve Outcomes after multi-ligament kNee injury (LION Trial). Trials. 2026. PMID: 41981668. doi:10.1186/s13063-026-09714-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。